Understanding Rheumatoid Arthritis
I realized I've never written a post specifically on rheumatoid arthritis (RA), even though it's the condition I treat most. Here's what it is, how it shows up, how it gets diagnosed, and how I approach treatment.
What is RA?
Rheumatoid arthritis is an autoimmune disease. Your immune system, instead of defending you against outside threats, mistakenly attacks the synovium, the thin lining inside your joints. That attack causes inflammation, and over time, untreated inflammation damages the joint itself, cartilage, bone, and the surrounding structures.
It's not the same disease as osteoarthritis, even though people often lump them together. Osteoarthritis is wear and tear on a joint over time. RA is your own immune system actively causing the damage, which is also why RA needs a different kind of treatment, one that calms the immune system down, not just one that manages symptoms.
What causes it?
RA is partly genetic, but genetics alone don't explain it. Here's a simple way to see that: identical twins share 100% of their genes. If genetics were the whole story, when one twin gets RA, the other would too, almost always. Instead, the other twin only develops it around 20% of the time. That gap is environment at work.
Tobacco is the best-established environmental trigger, covered in more depth in the substances post. A few others show up in the research too:
Periodontal (gum) disease, along with certain shifts in the gut microbiome, has been linked to higher RA risk.
Occupational exposure to silica dust raises risk in certain jobs.
Epstein-Barr virus (EBV), the virus that causes mono, is the most studied viral trigger. Active or recent EBV infection has been found to be nearly 5 times more common in RA patients than in people without the disease.
Air pollution, particularly fine particulate matter, has been linked to both the risk of developing RA and to disease activity and flares in people who already have it. This is increasingly relevant here in Minnesota: wildfire smoke events, largely drifting down from Canada, have become more frequent in recent years. On days with poor air quality, limit time outdoors, avoid outdoor exertion, and keep windows closed with your AC on recirculate. A regular dust mask or cloth covering won't filter out the fine particles that matter here, an N95 does.
None of these acts alone, they interact with genetic susceptibility rather than causing RA by themselves.
How might it show up?
The classic pattern is symmetric. RA tends to affect the same joints on both sides of the body at the same time, most often the small joints of the hands and feet, the knuckles, the base of the fingers, the balls of the feet. It can spread to wrists, knees, and other joints as it progresses.
Morning stiffness is a big clue. Stiffness that lasts more than 30 to 60 minutes after waking up, sometimes several hours, is a hallmark of RA. That's different from osteoarthritis, where stiffness usually clears up within a few minutes.
It usually builds gradually. Most people notice stiffness and mild swelling creeping in over weeks to months, not overnight. A smaller number of patients have a more sudden onset. Alongside the joint symptoms, fatigue, low-grade fever, and just feeling generally run down are common (we call this malaise), sometimes before the joint symptoms are even obvious.
RA can show up outside the joints too. At an initial visit, I'll usually ask about dry eyes or mouth, red or painful eyes, a dry cough or shortness of breath, and rashes or skin nodules. None of these are required for a diagnosis, but they're part of the full picture, and they can point toward RA or a related condition even when the joint symptoms alone aren't clear yet.
Some patients have symptoms for years before RA is officially diagnosable. Certain antibodies can show up in bloodwork long before any joint swelling appears, sometimes with vague joint pain that hasn't turned into anything a doctor can formally diagnose yet. This isn't limited to antibody-positive patients, similar findings show up on imaging in antibody-negative patients too, they're just harder to catch in advance without a blood marker to flag them. Not everyone who develops RA goes through this, but for those who do, the disease can be building quietly before there's anything to point to.
The visible deformities people associate with RA are uncommon now. When I do see them, it's almost always in patients who either declined treatment or were diagnosed late in the disease course. The earlier RA is caught and treated, the better the long-term outcome, which is a big part of why getting the diagnosis right matters as much as it does.
How is it diagnosed?
This is where I want to clear something up, because it trips up a lot of patients: blood tests don't diagnose RA by themselves.
Diagnosis rests on history and exam. Everything else, labs, imaging, either supports the diagnosis or argues against it, but none of it stands alone.
History is very important. The pattern of joints involved, how long symptoms have been going on, and how they've progressed all matter as much as any test result.
Exam looks for actual signs of inflammation, not just pain. Very early in the disease, though, that inflammation can be subtle enough to miss on exam alone.
Positive antibody tests (RF and anti-CCP) support the diagnosis, but a positive result by itself doesn't equal RA. These antibodies can show up in other conditions, and in a small number of people with no disease at all.
Negative antibody tests don't rule RA out either. Around 20% to 30% of people with RA test negative for both RF and anti-CCP. This is called seronegative RA, managed the same way as antibody-positive RA.
A normal X-ray doesn't rule out RA. X-rays show joint damage, and damage takes time to develop. Early in the disease, X-rays are often completely normal even when RA is actively present.
This is where advanced imaging helps. Joint ultrasound or MRI can pick up inflammation before it's obvious on exam and long before it would ever show up on an X-ray. I use ultrasound in the office for exactly this reason.
Treatment
For most patients, we start with methotrexate. It's the standard first-line DMARD (disease-modifying antirheumatic drug) for moderate to high disease activity, and it has decades of data behind it. If you have questions or concerns about it, I wrote a full post addressing them, Let's Talk About Methotrexate: Separating Fact From Fear, it's a much more reasonable medication than its reputation suggests.
For mild, low-activity disease, hydroxychloroquine can be a reasonable starting point instead. It's gentler, very well tolerated, and appropriate when the disease isn't aggressive. It's not as strong a disease-modifier as methotrexate, so it's reserved for cases that don't need that level of treatment.
Sometimes we'll try another conventional DMARD, like leflunomide, sulfasalazine, or azathioprine, before moving to a biologic. But most of the time, if someone isn't responding well to methotrexate, I move straight to a biologic rather than working through several conventional options first.
If methotrexate alone isn't enough, we escalate to a biologic. These target specific parts of the immune response more precisely. Staying on methotrexate alongside a biologic isn't redundant. Methotrexate reduces the immune system's tendency to build antibodies against the biologic itself, which means the biologic keeps working longer and more reliably than it would alone. This effect is well documented for TNF inhibitors specifically (a common class of biologic that blocks a key inflammatory signal called TNF).
There's also a newer option for patients who've failed or can't tolerate biologics: the SetPoint System, an FDA-approved vagus nerve stimulation implant, the first non-drug device treatment for RA. I wrote a full, independent review of the trial data and who I think is a good candidate for it, The SetPoint System for Rheumatoid Arthritis: A Rheumatologist's Review. Short version: it's a real option for the right patient, not a replacement for medication for most people.
Lifestyle factors
I've written a whole series on this: sleep, movement, nutrition, stress management, avoiding risky substances, and social connection, so I won't repeat it all here. The short version: these factors help lower inflammation and improve how you feel. I use them alongside medication, not instead of it. In rare cases, patients with well-controlled, mild disease are able to maintain that control with lifestyle changes and little to no medication. That's the exception, not something to expect or plan around.
The biggest misconception I see
Patients avoiding methotrexate entirely, or stopping it too soon, because of its reputation. A lot of that fear comes from confusing rheumatology doses with cancer doses, which are worlds apart (covered in detail in the post linked above). For a lot of patients, methotrexate alone is enough to control their disease. For others, it's what makes the next medication work better and last longer. Skipping it usually means starting from a weaker position, not a safer one.
A lot of that fear specifically comes down to side effects. Side effects can happen with any medication, that's not unique to methotrexate. If one shows up, we usually try to troubleshoot it first, increasing folic acid, changing the timing of the dose, splitting it into two doses instead of one, or switching to the injectable form. A lot of side effects resolve with one of those adjustments. If the side effect is still there after that, we stop the medication, we don't push through it indefinitely. But you don't know how you'll do on it until you try. I've had plenty of patients do really well on methotrexate alone, and they'd have missed out on that if the fear alone had kept them from starting.
Bottom line
RA is your immune system attacking your own joints, not wear and tear you just have to live with. A lab result alone can't confirm or rule it out, and for most patients, treatment starts with methotrexate, for good reason.
Sources
Cleveland Clinic, "Rheumatoid Arthritis (RA): Symptoms, Stages & Treatment." Overview of RA as an autoimmune disease affecting the synovium.
Johns Hopkins Arthritis Center, "Rheumatoid Arthritis Symptoms." Describes typical morning stiffness duration, insidious onset, symmetric joint pattern, and extra-articular manifestations.
van Steenbergen HW, et al. "EULAR definition of arthralgia suspicious for progression to rheumatoid arthritis." Annals of the Rheumatic Diseases, 2017. Formal criteria defining the symptomatic at-risk phase before clinical RA, which requires anti-CCP positivity.
van Steenbergen HW, et al. "Subclinical inflammation on MRI of hand and foot of anticitrullinated peptide antibody-negative arthralgia patients at risk for rheumatoid arthritis." Arthritis Research & Therapy, 2014. Found subclinical inflammation on MRI in antibody-negative at-risk patients, suggesting this pre-RA phase isn't exclusive to antibody-positive disease.
MacGregor AJ, et al. "Characterizing the quantitative genetic contribution to rheumatoid arthritis using data from twins." Arthritis & Rheumatism, 2000. Landmark twin study; more recent studies have found concordance rates in monozygotic twins ranging from about 15% to 30% depending on methodology.
Stolt P, et al. "Silica exposure is associated with increased risk of developing rheumatoid arthritis: results from the Swedish EIRA study." Annals of the Rheumatic Diseases. Found occupational silica exposure associated with elevated RA risk.
"Host-microbiota interactions in rheumatoid arthritis." Experimental & Molecular Medicine, 2019. Reviews evidence for gut and oral microbiome composition, including periodontal bacteria, in RA development.
Markers of Epstein-Barr Virus Infection in Association with the Onset and Poor Control of Rheumatoid Arthritis: A Prospective Cohort Study. Microorganisms, 2023. Found active/recent EBV infection nearly 5 times more common in RA patients than controls.
"Rheumatoid arthritis: Air pollution drives activity spikes, flare risk." Summarizing a study in Annals of the Rheumatic Diseases finding fine particulate matter (PM2.5) exposure associated with increased RA disease activity and flare risk.
Minnesota Pollution Control Agency, "A smoky summer ahead? What wildfire season could mean for air quality." Confirms wildfires affecting Minnesota air quality have grown larger and more frequent in recent years. American Lung Association guidance on protecting against wildfire smoke, including that cloth masks and dust masks don't filter fine particles the way an N95 does.
Elhai M, et al. "An Atypical Presentation of Seronegative Rheumatoid Arthritis." PMC, 2023. Found 15-30% of RA patients are seronegative for RF and anti-CCP, with clinical judgment necessary to avoid diagnostic delay.
RheumNow, "Hydroxychloroquine for Everyone." Confirms 2021 ACR guidelines prefer methotrexate over hydroxychloroquine as monotherapy for RA, with hydroxychloroquine appropriate for low disease activity.
Chinoy H. "The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases." Rheumatology, 2014. Reviews evidence that concomitant methotrexate reduces anti-drug antibody formation against TNF inhibitors, prolonging their effectiveness.
Arthritis Foundation, "Methotrexate: Managing Side Effects." Describes standard strategies for managing methotrexate side effects, including folic acid supplementation, dose splitting, and switching to the injectable form.
